Drug Type Autologous CAR-T |
Synonyms CRISPR (HPK1) edited CD19specific CART cell therapyXiAn Yufan Biotechnology + [1] |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), HPK1 inhibitors(Mitogen-activated protein kinase kinase kinase kinase 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Lymphoma | Phase 1 | CN | 01 Aug 2019 | |
CD19 Positive B-Cell Leukemia | Phase 1 | CN | 01 Aug 2019 | |
CD19 Positive Lymphoma | Phase 1 | CN | 01 Aug 2019 | |
Refractory acute lymphoid leukemia | Phase 1 | CN | 01 Aug 2019 |
NCT04037566 (ASCO2022) Manual | Phase 1 | 11 | (eqdhrnzpol) = xcflqinucg oaowmhognj (nsdwmdwjsn ) View more | Positive | 02 Jun 2022 | ||
Tecartus | (eqdhrnzpol) = jllmzchdwp oaowmhognj (nsdwmdwjsn ) View more |